Search Results: Zolgensma

Meet the Scientists Behind SMA Research and Discover What’s Coming Next

Posted in , ,

The Family-Friendly Poster Session is one of the most anticipated events at the Annual SMA Conference! This year’s session will be held on Friday, June […]

Cure SMA Awards $150,000 Grant to Emma Sutton, PhD, at Ottawa Hospital Research Institute in Canada

Posted in , , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]

Cure SMA Awards $150,000 Grant to Anton Blatnik, PhD, at Case Western Reserve University

Posted in , , ,

Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]

Itvisma®

Itvisma® Itvisma® is an FDA approved treatment for spinal muscular atrophy (SMA). It is a type of treatment referred to as gene therapy or gene […]

Novartis Gene Therapies Releases Spring SMA Community Letter

Posted in ,

Novartis Gene Therapies recently released an update to the SMA community related to clinical trials and long term follow up studies of Zolgensma, in addition […]

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Posted in ,

  New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA […]

Our History

Make today a breakthrough. Cure SMA was founded in 1984 to support the SMA community and fund research to find a cure. In our 40-year […]

SMA Scientists and Clinicians from Around the World Gather at the 27th Annual SMA Research & Clinical Care Meeting

Posted in , ,

At the end of June, SMA researchers and clinicians from around the world met in Orlando, Florida, for the 2023 Annual SMA Research & Clinical […]

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

Posted in , ,

Biogen Inc. announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA […]

Cure SMA International Resources

Welcome and thank you for reaching out to Cure SMA! The diagnosis of spinal muscular atrophy (SMA) can be confusing, scary, frustrating, pretty much the […]

Scroll to Top